Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
about
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitorsReplication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agentsIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variantsIn vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in BrazilDrug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sitesIn vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolatesHIV-1 Protease in the Fission Yeast Schizosaccharomyces pombeAltered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavirAn evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistanceVirological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitorsGenotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapySearch for the mechanism of genetic variation in the pro gene of human immunodeficiency virus.Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Antiretroviral resistance during successful therapy of HIV type 1 infection.Monitoring patients with HIV diseaseHuman immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapyMonitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapyVariant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor.Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteersPositive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisDrug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressureGenotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.Practical issues regarding the use of antiretroviral therapy for HIV infectionRapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors.Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.Molecular basis of adaptive convergence in experimental populations of RNA viruses.
P2860
Q24554340-E7A22F75-4C6F-4ABE-873C-52E6EAF7F795Q27469483-B3CB4D06-CCF6-48AB-BEE1-DCCA3173B71AQ28344457-43EAD12E-76DF-40E6-8A37-BCC11DCAD916Q28344472-02C8668B-E218-4388-8B4B-57457A914043Q28344594-818205FD-5BF9-4990-A3F8-78FF64E8882FQ28361560-97411F3C-F624-49FD-8D8B-EC18FFF104DEQ28368369-675D65A4-B7C7-4EEF-B2FC-AD9778A6B37DQ28369030-1B36DEDD-D8D4-4CCE-80A7-AB7498550454Q28369495-53A290DC-2AAA-4134-8AE4-9954CA61A241Q28369565-2C724C79-8C3E-4FA5-905A-AFB5F8A50F15Q28379086-AD3DD71D-CC4A-426E-BC87-28B7D472FF9EQ28379223-4921E6D6-A538-4753-812A-5C4B8F330624Q28550761-4390F8FA-3BF5-44BE-93DB-9E177A1E1D4EQ31033895-36D90B99-E661-458E-863B-24E5FCA1B5BCQ31963272-C6915ED1-48B9-40E8-94F6-8AAAB83EE2DAQ33307183-9AE733F2-9F1D-4974-A69C-05003AD3A4D0Q33592278-F26665EC-7201-4530-8C3E-5576C4FC3A51Q33667350-D6CA804B-3612-471D-9FBF-A9834925ADB2Q33769950-0A714E37-7AAB-47B9-984C-0597104FE9CAQ33770040-98436E16-1B04-47DA-91EC-7D5F817762C5Q33784635-6BB13BA1-56D3-480A-A91A-884A338A62F4Q33819390-C2CD9139-FF21-4305-9E35-620050F90676Q33843040-0040493D-5608-476D-898C-24F9C5F4240FQ33906239-237E6F4F-BD03-4EF5-9115-E34E13924989Q33919308-310911C0-9E67-4801-866B-3B9B82932DE8Q33925492-72C9D712-96EF-4FCD-859D-1C47A98143BFQ33962513-8EF3BFA7-D9E8-4EB9-9847-3FF99C80CA57Q33971104-81FF8849-AFB0-4639-828C-3D42A2AB1497Q33971117-3FCA7AAA-A7C6-4186-87D8-151A63A891A1Q33980528-9FB91FA8-3DA9-41A2-83CF-BAEA8AC05971Q33981706-A5C917F3-F30A-4612-B49A-52DB7B09DE53Q33983047-0B2E7694-D833-4B23-8DB0-AF7BEA733C7BQ34010283-C8698E95-2A88-4919-8979-E4A93B8057A2Q34012585-69E0DE9E-1778-4DB3-80F1-4A0EDFC40F20Q34034422-2B0A04E5-88E2-442B-BDB9-C79FCD39E88CQ34084316-7FA395F6-30E3-4297-9123-402CA722BEA5Q34187889-B53D52E2-443D-401E-B289-D75F0832CB53Q34454630-EA9919C8-4798-493D-A221-30FD6C483986Q34461427-E5AF5001-48E2-4146-93C3-2D2F0070075EQ34616146-E28639FA-393A-4643-997D-000916868AB8
P2860
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
description
1996 nî lūn-bûn
@nan
1996 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@ast
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@en
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@nl
type
label
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@ast
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@en
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@nl
prefLabel
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@ast
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@en
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@nl
P2093
P2860
P1433
P1476
Genetic correlates of in vivo ...... irus type 1 protease inhibitor
@en
P2093
D J Graham
D J Holder
F E Massari
H L Robbins
J A Chodakewitz
P2860
P304
P407
P577
1996-12-01T00:00:00Z